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SCIENTIFIC OPINION 
Scientific Opinion on the modification of the authorisation of a health claim 
related to plant sterol esters and lowering blood LDL-cholesterol; high 
blood LDL-cholesterol is a risk factor in the development of (coronary) 
heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006, 
following a request in accordance with Article 19 of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific opinion, published on 13 May 2014, replaces the earlier version published on 20 February 2014* 
ABSTRACT 
Following an application from SANOFI-AVENTIS FRANCE, submitted pursuant to Article 19 of Regulation 
(EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the modification of the authorisation of a health claim 
related to plant sterol esters and lowering blood LDL-cholesterol (high blood LDL-cholesterol is a risk factor in 
the development of (coronary) heart disease), pursuant to Article 14 of Regulation (EC) No 1924/2006. The 
applicant requested an extension of the conditions of use to powder supplements to be diluted in water at a dose 
of 2 g per day, which would lower blood LDL-cholesterol concentrations by “5.4-8.1 %” after six weeks of daily 
consumption. Plant sterol esters are sufficiently characterised. Lowering blood LDL-cholesterol concentrations is 
a beneficial physiological effect and elevated blood LDL-cholesterol concentration is a risk factor for coronary 
heart disease. The target population is subjects who need and want to lower their blood cholesterol. In weighing 
the evidence, the Panel took into account that only one human intervention study showed a reduction in blood 
LDL-cholesterol concentrations after six weeks of consuming 2 g/day of plant sterol esters in powder, the large 
uncertainty surrounding the estimates of this effect, and that the results of that study have not been replicated in 
                                                     
1 On request from the Competent Authority of France  following an application by SANOFI-AVENTIS FRANCE, Question 
No EFSA-Q-2013-00595, adopted on 5 February 2014. 
2 Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, 
Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna 
Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, 
Dominique Turck and Hans Verhagen. One member of the Panel did not participate in the discussion on the subject 
referred to above because of potential conflicts of interest identified in accordance with the EFSA policy on declarations of 
interests. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis 
Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso 
Siani, Anders Sjödin, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, and Peter Willatts for the preparatory work on 
this scientific opinion.  
* Minor changes of editorial nature were made. The changes do not affect the contents of this report. To avoid confusion, the 
original version of the opinion has been removed from the website, but is available on request, as is a version showing all 
the changes made. 
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other studies. The Panel reiterates its previous conclusion that, while plant sterols added to foods such as 
margarine-type spreads, mayonnaise, salad dressings, and dairy products have been shown consistently to lower 
blood LDL-cholesterol concentrations in a large number of studies, the effective dose of plant sterols (as powder 
diluted in water) needed to achieve a given magnitude of effect in a given timeframe cannot be established with 
the data provided.  
KEY WORDS 
plant sterol esters, powder, coronary heart disease, LDL-cholesterol 
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SUMMARY 
Following an application from SANOFI-AVENTIS FRANCE, submitted pursuant to Article 19 of 
Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic 
Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the modification of the 
authorisation of a health claim related to plant sterol esters and lowering blood LDL-cholesterol (high 
blood LDL-cholesterol is a risk factor in the development of (coronary) heart disease), pursuant to 
Article 14 of Regulation (EC) No 1924/2006, which was authorised by Regulation (EC) No 376/2010 
amending Regulation (EC) No 983/2009 and Regulation (EC) No 384/2010. 
The applicant requested an extension of the conditions of use to an additional food matrix (i.e. powder 
supplements to be diluted in water) at a dose of 2 g per day, and which would lower blood LDL-
cholesterol concentrations by “5.4-8.1 %” after six weeks of daily consumption.    
The application included a request for the protection of proprietary data. 
The Panel considers that plant sterol esters, the food constituents which are the subject of the health 
claim, are sufficiently characterised. 
The Panel considers that lowering blood LDL-cholesterol concentrations is a beneficial physiological 
effect, and that elevated blood LDL-cholesterol concentration is a risk factor for coronary heart 
disease. The target population is subjects who need and want to lower their blood cholesterol. 
The applicant identified one unpublished study as being pertinent to the health claim. 
In this multi-centre, double-blind, placebo-controlled study, 253 subjects were randomised to 
consume a powder with either plant sterol esters at doses of 2 g/day (n = 86) or 2.4 g/day (n = 86), or 
placebo (n = 81), at the two main meals of the day for six weeks. The primary outcome was changes 
in LDL-cholesterol (LDL-c) concentrations between the intervention groups and placebo.  
The analyses of the primary outcomes were presented for all randomised subjects (intention to treat, 
ITT), for the population of completers (n = 213) and for the per protocol (PP) population (n = 161). 
Compared with placebo, LDL-c concentrations in the 2 g/day group significantly decreased by 
8.22 ± 3.61 mg/dL (95 % CI: 1.11, 15.32; p = 0.0235) in the ITT population, by 8.08 ± 4.09 mg/dL 
(95 % CI: 0.02, 16.13; p = 0.0494) in the population of completers, and by 11.40 ± 4.84 mg/dL 
(95 % CI: 1.84, 20.97; p = 0.0197) in the PP population. Differences in changes of LDL-c 
concentrations during the study between the two intervention groups were not statistically significant.  
The Panel notes that this study shows a significant reduction in LDL-c concentrations of 4.8 % 
(95 % CI: 0.46 %, 9.64 %), 5.4 % (95 % CI: 0.2 %, 11.1 %) and 7.4 % (95 % CI: 0.5 %, 14.3 %) in 
the different populations analysed (ITT, population of completers and PP population, respectively), 
during continuous consumption of plant sterol esters in powder for six weeks at doses of 2 g/day.  
The applicant also provided three human intervention studies as being supportive of the health claim. 
These studies investigated the effect of various types of phytosterols in different formats which did 
not comply with the specifications provided by the applicant for the extension of the conditions of 
use. The Panel considers that no conclusions can be drawn from these studies for the scientific 
substantiation of the extension of the conditions of use proposed by the applicant.  
A meta-analysis including the four intervention studies mentioned above was provided by the 
applicant as being supportive of the health claim. The Panel notes that this meta-analysis includes 
only one study carried out with the food and matrix for which the extension of the conditions of use is 
requested, and thus it does not provide additional information for the scientific substantiation of the 
extension of the conditions of use to plant sterol esters in powder. 
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In weighing the evidence, the Panel took into account that only one human intervention study showed 
a reduction in blood LDL-c concentrations of 4.8 % (95 % CI: 0.46 %, 9.64 %), 5.4 % 
(95 % CI: 0.2 %, 11.1 %) and 7.4 % (95 % CI: 0.5 %, 14.3 %) in the different populations analysed 
after six weeks of consuming 2 g/day of plant sterol esters in powder, the large uncertainty 
surrounding the estimates of this effect, and that these results have not been replicated in other 
studies.  
The Panel reiterates its previous conclusion that, while plant sterols added to foods such as margarine-
type spreads, mayonnaise, salad dressings, and dairy products such as milk, yoghurts, including 
low-fat yoghurts, and cheese have been shown consistently to lower blood LDL-c concentrations in a 
large number of studies, the effective dose of plant sterols (as powder diluted in water) needed to 
achieve a given magnitude of effect in a given timeframe, cannot be established with the data 
provided.  
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims.  
The same Regulation, as referred to in Article 19, also lays down provisions for modification, 
suspension and revocation of authorisations. The procedures laid down in Article 15 and 18 shall 
apply mutatis mutandis. 
According to Article 15 of that Regulation, an application for the modification, suspension or 
revocation of authorisations of health claims included in the Community list of permitted claims 
referred shall be submitted by the applicant to the national competent authority of a Member State, 
who will make the application and any supplementary information supplied by the applicant available 
to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 10/06/2013. 
 The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction. 
 On 10/07/2013, during the validation process of the application, EFSA sent a request to the 
applicant asking it to provide missing information. 
 On 22/07/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 24/07/2013. 
 On 25/09/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock was stopped on 08/10/2013 in compliance with Art. 16(1) of Regulation (EC) 
No 1924/2006.  
 On 29/10/2013, EFSA received the requested information as submitted by the applicant and 
the clock was restarted.  
 On 22/11/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the clock 
was stopped on 04/12/2013 in compliance with Art. 16(1) of Regulation (EC) No 1924/2006.  
 On 03/01/2014, EFSA received the requested information as submitted by the applicant and 
the clock was restarted.  
 During its meeting on 05/02/2014, the NDA Panel, after having evaluated the overall data 
submitted, adopted an opinion on the scientific substantiation of a health claim related to 
plant sterol esters and lowering blood LDL-cholesterol under the new conditions of use 
proposed by the applicant. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made 
on foods. OJ L 404, 30.12.2006, p. 9–25. 
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TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 19 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the modification of the authorisation of a health claim related to plant sterol esters and 
lowering blood LDL-cholesterol; high blood LDL-cholesterol is a risk factor in the development of 
(coronary) heart disease, which was authorised by Regulation (EC) No 376/2010 amending 
Regulation (EC) No 983/2009 and Regulation (EC) No 384/2010..  
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of plant sterol esters, a positive assessment of their safety, nor a decision on whether plant sterol 
esters are, or are not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: SANOFI-AVENTIS FRANCE, 9 Boulevard Romain Rolland, 
75159, Paris, Cedex 14, France.  
The application includes confidential and proprietary data. The applicant claims confidentiality and 
proprietary rights for the unpublished study report by Bruckert (2012) and the unpublished 
meta-analysis by Cucherat (2013). The applicant also claimed confidentiality rights for information 
pertaining to the manufacturing process.  
Food/constituent as stated by the applicant 
According to the applicant, the food constituent that is the subject of the health claim is plant sterol 
esters presented as a food supplement in a powder sachet. Plant sterols are esterified with food-grade 
fatty acids of vegetable oil origin. 
The applicant has provided the composition of plant sterol esters for which the health claim is made, 
and which has been authorised under the Novel Food Regulation EC 258/97, for the placing on the 
market of various products with added phytosterols/phytostanols (Decision 2000/500/EC, 2004/333-
336/EC, 2004/845/EC, 2006/58-59/EC, 2007/343/EC and 2008/36/EC): β-sitosterol < 80 %, 
β-sitostanol < 15 %, campesterol < 40 %, campestanol < 5 %, stigmasterol < 30 %, brassicasterol 
< 3 %, and other phytosterols < 3 %.  
In the context of this dossier, the quantities of plant sterol esters are expressed as equivalent weights 
of free (unesterified) sterols.  
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect concerns the reduction effect size in blood low density 
lipoprotein-cholesterol (LDL-c) with the consumption of plant sterol esters presented as a food 
supplement in a powder sachet. Blood concentration of LDL-c is the outcome measured to assess the 
claimed effect in humans. Elevated blood LDL-c is a risk factor for coronary heart disease (CHD), 
which is an important cause of mortality and morbidity. Lowering LDL-c by dietary intervention has 
been shown to reduce the risk of coronary heart disease. Lowering LDL-c is considered by the EFSA 
NDA Panel as beneficial to human health in its scientific opinions (EFSA, 2008a, b, 2009a).  
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Plant sterol esters presented 
as food supplement in powder sachet have been shown to lower/reduce blood cholesterol. High 
cholesterol is a risk factor in the development of coronary heart disease”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population for which the health claim is requested are people 
with mildly raised blood LDL-c concentration who need and want to lower their blood cholesterol. 
Patients on cholesterol-lowering medication should consume the product only under medical 
supervision (EFSA, 2008a, b, 2009a).  
The applicant has proposed new conditions of use to obtain the claimed effect: 
Plant sterol esters and blood cholesterol  
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 the consumption of a daily intake of 2.0 g of plant sterol esters (expressed as the weight of 
free equivalents) presented as food supplement in powder sachet, which can reasonably be 
part of a balanced diet due to a very low calorie intake of this matrix; 
 when referring to the magnitude of the effect, the range “5.4-8.1 %” and the duration of 
consumption of six weeks to obtain the effect will be communicated to the consumer. 
Specific statements shall be addressed according to the Commission Regulation (EC) No. 608/2004 
concerning the labelling of foods and food ingredients with added phytosterols, phytosterol esters, 
phytostanols and/or phytostanol esters.  
ASSESSMENT 
The applicant proposed a change in the conditions of use for claims made on food products with 
added plant sterol esters as authorised by Regulation (EC) No 376/2010, amending Regulation (EC) 
983/2009, and Regulation (EC) No 384/2010. The authorised claim is: “Plant sterols/plant stanol 
esters have been shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the 
development of coronary heart disease”. The conditions of use of the claim are: “Information to the 
consumer that the beneficial effect is obtained with a daily intake of 1.5-2.4 g plant sterols/stanols. 
Reference to the magnitude of the effect may only be made for foods within the following categories: 
yellow fat spreads, dairy products, mayonnaise and salad dressings. When referring to the magnitude 
of the effect, the entire range “7 to 10 %” and the duration to obtain the effect “in 2 to 3 weeks” must 
be communicated to the consumer”. 
The applicant requested an extension of the conditions of use to an additional food matrix (i.e. powder 
supplements to be diluted in water) at a dose of 2 g per day, and which would lower blood LDL-
cholesterol (LDL-c) concentrations by “5.4-8.1 %” after six weeks of daily consumption.    
1. Characterisation of the food/constituent  
The food constituent that is the subject of the health claim is plant sterol esters from natural sources 
with a composition as specified in the Commission Decisions authorising the placing on the market of 
food products with added plant sterols under Regulation (EC) No 258/97 (Commission Decisions 
2000/500/EC, 2004/333-336/EC, 2004/845/EC, 2006/58-59/EC, 2007/343/EC and 2008/36/EC) and 
subsequent products authorised under Regulation (EC) No 258/97 for the placing on the market of 
products with added plant sterols.  
The Panel considers that plant sterol esters, the food constituents for which the health claim is 
proposed, are sufficiently characterised. 
Throughout this opinion, quantities of plant sterols esters are expressed as the equivalent weights of 
free [i.e. non-esterified] sterols. 
2. Relevance of the claimed effect to human health 
The Panel considers that lowering blood LDL-c concentrations is a beneficial physiological effect, 
and that elevated blood LDL-c is a risk factor for coronary heart disease (EFSA, 2008a, b, 2009a). 
The target population is subjects who need and want to lower their blood cholesterol. 
3. Scientific substantiation of the claimed effect 
The scientific substantiation of this claim focuses on the efficacy of 2 g per day of plant sterol esters 
in powder on LDL-c lowering and on the minimum duration of the intervention for the effect to occur. 
Plant sterol esters and blood cholesterol  
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The applicant performed a literature search in PubMed and NCBI databases, without applying any 
time restrictions, by combining specific search terms related to “phytosterols”, “powder” and “food 
supplement”. No publications related to the use of plant sterol esters in powder were retrieved through 
the literature search.  
The applicant provided an unpublished study report (Bruckert, 2012) on the effect of plant sterol 
esters in powder on blood LDL-c concentrations.  
The multi-centre, randomised, double-blind, placebo-controlled study by Bruckert (2012) investigated 
the effect of two doses (2 g/day and 2.4 g/day) of plant sterol esters in powder on blood LDL-c 
concentrations in subjects with LDL-c concentrations ≥ 160 mg/dL. Subjects on cholesterol-lowering 
medications, and subjects who had consumed phytosterols as food supplements or as enriched foods 
within the six weeks prior to enrolment, were excluded from the study. At the screening visit blood 
samples were collected for a serum lipid assay performed in a local laboratory, unless subjects had a 
lipid test performed less than three months before the visit.  
A total of 253 subjects meeting the inclusion criteria were randomised to consume either plant sterol 
esters at doses of 2 g/day (n = 86) or 2.4 g/day (n = 86) or placebo (n = 81). The study products were 
provided as powder in sachets containing 1 g or 1.2 g of plant sterol esters, or a mixture of skimmed 
milk powder and maltodextrin (placebo), and were consumed twice a day at the two main meals for 
42 consecutive days. Fasting blood samples were collected at baseline and on day 43 of the study 
(assays performed in a central laboratory). Compliance was evaluated by counting the remaining 
sachets at the final visit.  
Power calculations were performed assuming an 8 % difference in LDL-c concentrations between the 
two intervention groups and placebo, a mean baseline LDL-c concentration of 175 mg/dL and a SD of 
23 mg/dL, a dropout rate of 5 %, a power of 90 % and  = 0.025. It was calculated that 70 subjects 
per group would be needed to detect differences in LDL-c changes between the intervention groups 
and placebo, and that 74 subjects per group would be required to detect differences between the two 
intervention groups (secondary outcome). The primary outcome of the study was changes in LDL-c 
concentrations between the intervention groups and placebo. Secondary outcomes were changes in 
blood concentrations of high-density lipoprotein-cholesterol (HDL-c), total cholesterol, triglycerides 
and phytosterols (lathosterol, sitosterol, campesterol).  
Among the 253 subjects randomised, seven (two in each intervention group and three in the placebo 
group) did not take the study products, two subjects in the 2 g/day group were excluded owing to 
administrative violations, and 31 subjects (nine in the 2 g/day group, 14 in the 2.4 g/day group, and 
eight in the placebo group) were excluded because LDL-c concentrations were not available either at 
baseline (n = 14), at the end of the study (n = 14) or at both time points (n = 3). Upon a request by 
EFSA for clarification on the missing values, the applicant indicated that missing values for LDL-c 
analysed by the central study laboratory, either at baseline or at the end of the study, was a pre-
planned exclusion criterion; that the characteristics of subjects excluded for this reason were 
comparable across study groups and between the subjects retained and excluded, and thus the 
distribution of missing data could be assumed to be at random; and that any method used post-hoc for 
imputing missing values would have been more prone to bias than the exclusion of subjects as 
planned. Two subjects in each intervention group and five subjects in the placebo group had < 80 % 
compliance with the study products. 
The analyses of the primary and secondary outcomes were presented for the population of completers 
(n= 213; 73 subjects in the 2 g/day group, 70 subjects in the 2.4 g/day and placebo groups) and for the 
per protocol (PP) population (n = 161; 58 subjects in the 2 g/day group, 52 subjects in the 2.4 g/day 
group, and 51 subjects in the placebo group). The study groups were not significantly different at 
baseline regarding age, sex, body mass index (BMI) or LDL-c concentrations.   
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Differences between each intervention group and placebo regarding changes in LDL-c concentrations 
during the study were assessed by using analysis of covariance (ANCOVA) adjusting for baseline 
LDL-c concentrations (primary analysis). An explanatory analysis comparing the 2 g/day vs. the 2.4 
g/day group was also planned by using the same model as for the primary analysis. Results were given 
as mean differences ± SD and 95 % CI.  
Compared with placebo, LDL-c concentrations significantly decreased by 8.08 ± 4.09 mg/dL in the 
2 g/day group (95 % CI: 0.02, 16.13; p = 0.0494) and by 10.12 ± 4.12 mg/dL in the 2.4 g/day group 
(95 % CI: 1.99, 18.25; p = 0.0150) in the population of completers. LDL-c concentrations also 
decreased significantly in the 2 g/day group (by 11.40 ± 4.84; 95 % CI: 1.84, 20.97; p = 0.0197) and 
in the 2.4 g/day group (by 13.83 ± 4.97; 95 % CI: -4.02, 23.64; p = 0.0060) compared with placebo 
when the PP population was considered. Differences in changes of LDL-c concentrations between the 
two intervention groups were not statistically significant. Upon a request by EFSA for clarification on 
the statistical analyses, the applicant provided a statistical analysis of the differences between each 
intervention group and placebo regarding changes in LDL-c concentrations including all subjects who 
were randomised (ITT, intention to treat). The analysis was performed using an ANCOVA model 
adjusted for baseline, and by replacing the missing data with the median value of completers. 
Compared with placebo, LDL-c concentrations significantly decreased by 8.22 ± 3.61 mg/dL in the 2 
g/day group (95 % CI: 1.11, 15.32; p = 0.0235) and by 8.64 ± 3.58 mg/dL in the 2.4 g/day group 
(95 % CI: 1.58, 15.70; p = 0.0166).  
Results were also provided as percent changes from baseline. In the ITT population LDL-c 
concentrations decreased by 4.8 % (95 % CI: 0.46 %, 9.64 %) in the 2 g/day group and by 4.8 % 
(95 % CI: 0.00 %, 9.63 %) in the 2.4 g/day group compared with placebo. In the population of 
completers, LDL-c concentrations decreased by 5.4 % (95 % CI: 0.2 %, 11.1 %) in the 2 g/day group 
and by 5.5 % (95 % CI: 0.2 %, 11.3 %) in the 2.4 g/day group compared with placebo. In the PP 
population, LDL-c concentrations decreased by 7.4 % (95 % CI: 0.5 %, 14.3 %) in the 2 g/day group 
and by 7.5 % (95 % CI: 0.4 %, 14.6 %) in the 2.4 g/day group compared with placebo. 
An additional sub-group analysis was performed in the PP population to calculate differences in the 
percentage change of LDL-c between the intervention groups and placebo, which included only 96 
subjects with LDL-c concentrations ≥ 160 mg/dL at baseline as measured in the central laboratory 
(38% of the recruited subjects). During the evaluation process, EFSA requested the applicant to 
explain how this sub-group analysis could be used to estimate the effect of plant sterol esters at the 
proposed dose for the target population (i.e. subjects who need and want to lower their blood 
cholesterol). In the reply, and with reference to Regulation 718/2013, which foresees that products 
with added phytosterols, phytosterol esters, phytostanols and/or phytostanol esters, are not intended 
for people who do not need to control their blood cholesterol, the applicant explained that subjects 
with LDL-c concentrations < 160 mg/dL at baseline as measured in the central laboratory could be 
considered as people who do not need to control their blood cholesterol. The Panel notes that LDL-c 
concentrations < 160 mg/dL at baseline as measured in the central laboratory was not a criterion for 
stratifying subjects at randomisation. The Panel considers that this sub-group analysis cannot be used 
to estimate the effect of plant sterol esters at the proposed dose (2 g/day) for the target population, in 
which blood cholesterol concentrations are generally assessed as in the recruitment phase of this 
study.  
The Panel notes that this study shows a significant reduction in LDL-c concentrations of 4.8 % 
(95 % CI: 0.46 %, 9.64 %), 5.4 % (95 % CI: 0.2 %, 11.1 %) and 7.4 % (95 % CI: 0.5 %, 14.3 %) in 
the different populations analysed (ITT, population of completers and PP population, respectively), 
during continuous consumption of plant sterol esters in powder for six weeks at doses of 2 g/day.  
Three additional human intervention studies were identified by the applicant through the literature 
search as being supportive of the health claim (McPherson et al., 2005; Carr at al., 2009; Maki et al., 
2012). The Panel notes that these studies investigated the effect of various types of phytosterols (i.e. 
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esterified or free sterols and stanols, stanol-lecithin complex) in different formats (i.e. tablets or 
capsules), which do not comply with the specifications provided by the applicant for the extension of 
the conditions of use (i.e., plant sterol esters in powder). The Panel considers that no conclusions can 
be drawn from these studies for the scientific substantiation of the extension of the conditions of use 
proposed by the applicant.  
The applicant also provided an unpublished meta-analysis (Cucherat, 2013), which included the 
unpublished study by Bruckert (2012) and the three intervention studies which were retrieved through 
the literature search (McPherson et al., 2005; Carr at al., 2009; Maki et al., 2012).  
The Panel notes that the meta-analysis by Cucherat (2013) includes only one study (Bruckert, 2012) 
carried out with the food and matrix for which the extension of the conditions of use is requested. In 
this respect, EFSA invited the applicant to comment on how this meta-analysis could provide 
evidence for an extension of the conditions of use to plant sterol esters in powder for at the dose and 
for the size of the effect proposed. The applicant indicated that the meta-analysis was conducted to 
highlight that the evidence available is not sufficient to extent the conditions of use for the claim to 
dry extract supplements other than the power sachets. The Panel considers that this meta-analysis 
does not provide additional information for the scientific substantiation of the extension of the 
conditions of use to plant sterol esters in powder.  
In weighing the evidence, the Panel took into account that only one human intervention study showed 
a reduction in blood LDL-c concentrations of 4.8 % (95 % CI: 0.46 %, 9.64 %), 5.4 % 
(95 % CI: 0.2 %, 11.1 %) and 7.4 % (95 % CI: 0.5 %, 14.3 %) in the different populations analysed 
after six weeks of consuming 2 g/day of plant sterol esters in powder, the large uncertainty 
surrounding the estimates of this effect, and that these results have not been replicated in other 
studies.  
The Panel reiterates its previous conclusion (EFSA, 2009b) that, while plant sterols added to foods 
such as margarine-type spreads, mayonnaise, salad dressings, and dairy products such as milk, 
yoghurts, including low-fat yoghurts, and cheese have been shown consistently to lower blood 
LDL-cholesterol concentrations in a large number of studies, the effective dose of plant sterols (as 
powder diluted in water) needed to achieve a given magnitude of effect in a given timeframe, cannot 
be established with the data provided.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituents, plant sterol esters, which are the subject of the health claim, are 
sufficiently characterised. 
 Lowering of blood LDL-cholesterol concentrations is a beneficial physiological effect; an 
elevated blood LDL-cholesterol concentration is a risk factor for coronary heart disease.  
 While plant sterols added to foods such as margarine-type spreads, mayonnaise, salad 
dressings, and dairy products such as milk, yoghurts, including low-fat yoghurts, and cheese 
have been shown consistently to lower blood LDL-cholesterol concentrations in a large 
number of studies, the effective dose of plant sterols (as powder diluted in water) needed to 
achieve a given magnitude of effect in a given timeframe, cannot be established with the data 
provided. 
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DOCUMENTATION PROVIDED TO EFSA 
Health claim application on plant sterol esters and lowering blood LDL-cholesterol (high blood 
LDL-cholesterol is a risk factor in the development of (coronary) heart disease) pursuant to Article 14 
of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of the afore-
mentioned Regulation (Claim serial No: 0389_FR). June 2013. Submitted by SANOFI-AVENTIS 
FRANCE. 
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ABBREVIATIONS 
ANCOVA Analysis of covariance 
CHD  Coronary heart disease 
LDL-c  Low density lipoprotein-cholesterol  
HDL-c  High density lipoprotein-cholesterol 
ITT  Intention to treat 
PP  Per protocol 
